Index
S&P 500
Market Cap
17.93B
Enterprise Value
20.80B
Income
-238.46M
Sales
4.00B
Book/sh
59.50
Cash/sh
4.53
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
19700
IPO
Jun 23, 2000
P/E
-
Forward P/E
29.36
PEG
2.51
P/S
4.48
P/B
6.31
P/C
82.85
P/FCF
48.39
EV/EBITDA
24.81
EV/Sales
5.20
Quick Ratio
1.04
Current Ratio
1.35
Debt/Eq
1.07
LT Debt/Eq
1.07
Option/Short
Yes / Yes
EPS (ttm)
-4.85
EPS next Y
12.80
EPS next Q
2.97
EPS this Y
10.69%
EPS next Y
12.45%
EPS next 5Y
11.70%
EPS past 3/5Y
- -
Sales past 3/5Y
0.33% 6.55%
EPS Y/Y TTM
-268.79%
Sales Y/Y TTM
-0.74%
EPS Q/Q
-102.91%
Sales Q/Q
-2.72%
Insider Own
1.12%
Insider Trans
-26.54%
Inst Own
123.16%
Inst Trans
-2.01%
ROA
-3.16%
ROE
-7.70%
ROIC
-4.06%
Gross Margin
32.63%
Oper. Margin
13.51%
Profit Margin
-5.96%
SMA20
16.91%
SMA50
24.99%
SMA200
69.93%
Trades
Shs Outstand
47.73M
Shs Float
47.20M
52W High
378.23 -0.68%
52W Low
146.20 156.95%
Volatility
3.85% 4.39%
ATR (14)
13.34
RSI (14)
80.58
Beta
1.41
Rel Volume
0.51
Avg Volume
1.02M
Volume
386,263
Perf Week
10.60%
Perf Month
27.33%
Perf Quarter
61.56%
Perf Half Y
124.98%
Perf YTD
88.31%
Perf Year
108.52%
Perf 3Y
117.65%
Perf 5Y
-16.28%
Perf 10Y
394.27%
Prev Close
373.98
Price
375.65
Change %
0.45%
Consensus Strong Buy
Analysts 16 incl. previous ratings
Rating Distribution 14 Buy · 2 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 30, 2026 Resumed U UBS
Buy $357 -5.0% Aug 06, 2026 Upgrade J JP Morgan
Neutral → Overweight $310 -17.5% Jul 20, 2026 Downgrade C
Outperform → Hold $219 -41.7% Jun 17, 2026 Upgrade M Morgan Stanley
Equal-Weight → Overweight $220 -41.4% May 29, 2026 Upgrade C
Hold → Outperform $219 -41.7% Apr 14, 2026 Initiated R RBC Capital Mkts
Outperform $215 -42.8% Dec 15, 2025 Upgrade B BofA Securities
Neutral → Buy $225 -40.1% Nov 17, 2025 Upgrade A
Hold → Buy Nov 06, 2025 Upgrade R
Neutral → Outperform $199 -47.0% Oct 06, 2025 Upgrade W
Mkt Perform → Outperform Oct 02, 2025 Upgrade B Barclays
Equal Weight → Overweight $195 -48.1% Sep 09, 2025 Upgrade J Jefferies
Hold → Buy $195 -48.1% Jul 09, 2025 Upgrade C Citigroup
Neutral → Buy $200 -46.8% May 23, 2025 Upgrade R
Neutral → Buy $182 -51.6% May 14, 2025 Upgrade T TD Cowen
Hold → Buy $179 -52.3% May 08, 2025 Upgrade E Evercore ISI
In-line → Outperform $170 -54.7% Mar 21, 2025 Downgrade G Goldman
Buy → Neutral $190 → $170 -54.7% Mar 04, 2025 Upgrade C Citigroup
Sell → Neutral $155 → $175 -53.4% Mar 03, 2025 Upgrade R
Sell → Neutral $188 -50.0% Jan 22, 2025 Downgrade W
Outperform → Mkt Perform
Oct-27-26 01:05PM
08:00AM
Oct-22-26 04:30PM
Oct-20-26 04:30PM
(MarketWatch)
+5.14%
+9.33%
02:41PM
06:25AM
Loading…
Oct-14-26 06:25AM
(Pharmaceutical Technology)
Oct-13-26 08:00AM
Oct-09-26 08:00AM
Oct-06-26 08:00AM
Oct-05-26 04:30PM
Sep-24-26 04:30PM
08:00AM
Sep-17-26 08:00AM
Sep-11-26 08:00AM
Sep-08-26 08:00AM
08:00AM
Loading…
Aug-20-26 08:00AM
Aug-06-26 09:48AM
Aug-05-26 05:01PM
04:30PM
04:16PM
(Investor's Business Daily)
07:28AM
07:00AM
Jul-29-26 04:52PM
Jul-28-26 04:30PM
Jul-15-26 08:00AM
Jul-13-26 08:00AM
Jul-09-26 04:30PM
Jul-03-26 12:25PM
Jun-24-26 04:30PM
(MarketWatch)
+8.31%
+5.25%
08:05AM
02:18AM
Loading…
02:18AM
Jun-19-26 06:07AM
Jun-18-26 08:00AM
Jun-17-26 09:47AM
09:13AM
May-29-26 09:40AM
May-28-26 04:30PM
May-27-26 04:30PM
May-15-26 04:30PM
May-13-26 08:00AM
May-11-26 08:00AM
May-07-26 07:11AM
07:00AM
Apr-30-26 08:00AM
Apr-21-26 08:00AM
Apr-16-26 08:00AM
Apr-14-26 09:53AM
Apr-09-26 04:30PM
Apr-06-26 08:55AM
Mar-10-26 10:30AM
Mar-09-26 11:33PM
Mar-05-26 10:34AM
Mar-02-26 08:00AM
Feb-26-26 06:42AM
(Pharmaceutical Technology)
Feb-25-26 09:06AM
07:00AM
Feb-24-26 02:38PM
09:40AM
Feb-23-26 09:15AM
Feb-20-26 08:03AM
Feb-19-26 10:20PM
12:33AM
Feb-18-26 04:06PM
12:49PM
09:30AM
08:55AM
08:10AM
07:33AM
07:16AM
(Associated Press Finance)
07:01AM
07:00AM
Feb-16-26 10:05PM
09:15AM
Feb-15-26 08:58AM
Feb-13-26 09:39AM
07:01AM
(Private Banker International)
Feb-12-26 02:27PM
Feb-11-26 08:21PM
(Morningstar Research)
-8.42%
10:00AM
Feb-10-26 11:34PM
Feb-08-26 11:01PM
Feb-02-26 07:15AM
Jan-27-26 08:10AM
Jan-21-26 04:30PM
08:00AM
Jan-20-26 11:04AM
11:00AM
Jan-19-26 05:59AM
Jan-15-26 12:00PM
09:42AM
Jan-12-26 04:30PM
08:57AM
Jan-09-26 07:45AM
Jan-08-26 08:00AM
Jan-06-26 12:00PM
09:15AM
Dec-22-25 03:00PM
Dec-18-25 08:36AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
FOSTER JAMES C Director Oct 22 '26 Option Exercise 244.41 24,042 5,876,105 55,638 Oct 26 04:51 PM FOSTER JAMES C Director Oct 22 '26 Sale 350.00 24,042 8,414,700 31,596 Oct 26 04:51 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 21 '26 Option Exercise 244.41 2,156 526,948 6,963 Oct 23 06:45 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 21 '26 Sale 344.41 2,156 742,548 4,807 Oct 23 06:45 PM FOSTER JAMES C Director Oct 22 '26 Proposed Sale 350.00 24,042 8,414,700 Oct 22 04:03 PM Parisotto Shannon M Officer Oct 21 '26 Proposed Sale 344.41 2,156 742,548 Oct 21 04:05 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 05 '26 Option Exercise 208.44 981 204,480 5,788 Oct 07 08:32 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Oct 05 '26 Sale 308.44 981 302,580 4,807 Oct 07 08:32 PM Parisotto Shannon M Officer Oct 05 '26 Proposed Sale 314.56 981 308,580 Oct 05 04:25 PM Coleman Glenn EVP & Chief Financial Officer Sep 30 '26 Buy 297.43 10 2,974 27,762 Oct 02 04:27 PM FOSTER JAMES C Director Aug 25 '26 Option Exercise 199.42 33,561 6,692,845 65,157 Aug 27 04:21 PM FOSTER JAMES C Director Aug 25 '26 Sale 300.00 33,561 10,068,300 31,596 Aug 27 04:21 PM FOSTER JAMES C Director Aug 25 '26 Proposed Sale 299.93 33,561 10,065,951 Aug 25 04:10 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Aug 19 '26 Option Exercise 194.12 2,039 395,811 6,846 Aug 20 04:33 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Aug 19 '26 Sale 294.12 2,039 599,711 4,807 Aug 20 04:33 PM Andrews Nancy C Director Aug 18 '26 Option Exercise 164.30 573 94,144 2,011 Aug 20 04:31 PM Andrews Nancy C Director Aug 18 '26 Sale 285.24 573 163,443 1,438 Aug 20 04:31 PM Parisotto Shannon M Officer Aug 19 '26 Proposed Sale 294.12 2,039 599,711 Aug 19 04:15 PM Nancy C Andrews Director Aug 18 '26 Proposed Sale 285.00 573 163,305 Aug 18 11:06 AM Girshick Birgit Chief Executive Officer Aug 11 '26 Option Exercise 179.66 6,500 1,167,790 42,513 Aug 13 04:37 PM Girshick Birgit Chief Executive Officer Aug 11 '26 Sale 279.90 6,500 1,819,350 36,013 Aug 13 04:37 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Aug 11 '26 Option Exercise 179.66 3,714 667,257 8,521 Aug 13 04:34 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Aug 11 '26 Sale 279.66 3,714 1,038,657 4,807 Aug 13 04:34 PM FOSTER JAMES C Director Aug 10 '26 Option Exercise 179.66 28,733 5,162,171 60,329 Aug 11 04:35 PM FOSTER JAMES C Director Aug 10 '26 Sale 275.00 28,733 7,901,575 31,596 Aug 11 04:35 PM Parisotto Shannon M Officer Aug 11 '26 Proposed Sale 279.66 3,714 1,038,657 Aug 11 04:07 PM Girshick Birgit Officer Aug 11 '26 Proposed Sale 279.90 6,500 1,819,350 Aug 11 04:07 PM Knell Michael Gunnar SVP, Finance and CAO Aug 06 '26 Option Exercise 196.12 2,345 459,909 14,197 Aug 10 04:40 PM Knell Michael Gunnar SVP, Finance and CAO Aug 06 '26 Sale 260.38 6,645 1,730,250 11,852 Aug 10 04:40 PM Creamer Victoria L EVP & Chief People Officer Aug 06 '26 Option Exercise 179.66 4,179 750,799 34,230 Aug 10 04:35 PM Creamer Victoria L EVP & Chief People Officer Aug 06 '26 Sale 259.16 4,179 1,083,030 30,051 Aug 10 04:35 PM FOSTER JAMES C Director Aug 10 '26 Proposed Sale 275.00 28,733 7,901,575 Aug 10 04:29 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Aug 05 '26 Sale 263.00 5,046 1,327,098 4,807 Aug 06 04:49 PM Michael Knell Officer Aug 06 '26 Proposed Sale 260.00 6,645 1,727,700 Aug 06 03:09 PM Victoria Creamer Officer Aug 06 '26 Proposed Sale 260.00 4,179 1,086,540 Aug 06 03:09 PM Parisotto Shannon M Officer Aug 05 '26 Proposed Sale 263.00 5,046 1,327,098 Aug 05 04:02 PM FOSTER JAMES C Director Jun 29 '26 Sale 225.00 75,000 16,875,000 31,596 Jul 01 04:59 PM FOSTER JAMES C Director Jun 29 '26 Proposed Sale 225.00 75,000 16,875,000 Jun 29 04:44 PM LaPlume Joseph W EVP, Corp Strategy & Develop Mar 03 '26 Buy 174.54 25 4,364 27,448 Mar 04 04:39 PM
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
CEO & Director Ms. Birgit Girshick
Corporate Senior VP & Chief Accounting Officer Mr. Michael Gunnar Knell
Corporate Executive Vice President of Corporate Development & Strategy Mr. Joseph W. LaPlume J.D.
Corporate Executive VP & Chief People Officer Ms. Victoria L. Creamer
Corporate Executive VP & CFO Mr. Glenn G. Coleman CPA
